The Recovery Stack: BPC-157 and TB-500 for an Injury That Will Not Heal

Who this is for

The shoulder that has hurt for eight months. The Achilles that flares every time mileage goes back up. The elbow that was supposed to be fine by now.

You have done the physio. You have rested it. Somebody in a forum or a gym told you about a peptide stack, and you want to know whether there is anything real underneath it before you spend three hundred dollars on powder from a website you have never heard of.

This is not a protocol. It is what the evidence actually supports, what it does not, and where the real risk sits.

What people actually run

Reporting what circulates, not recommending it.

The pairing is BPC-157 and TB-500, run together, usually for four to eight weeks. It is commonly called the Wolverine stack, after the comic book character who heals from anything. Worth noticing that the name is doing persuasive work before a single number gets mentioned.

The conventions that circulate are roughly 250 to 500 mcg per day of BPC-157, and roughly 2 mg twice weekly of TB-500 for a loading period followed by a lower maintenance frequency. Subcutaneous, usually near the injury site, though the near-the-injury part has no support behind it either.

The reasoning offered for combining them is that they do different jobs. BPC-157 for blood vessel formation and local tissue repair, TB-500 for cell migration across a wider area. That is a tidy story. It is also assembled entirely from mechanism, not from any study that tested the pair.

What each one is actually built on

BPC-157. A 15 amino acid synthetic peptide with a large body of rodent work, almost all of it from a single laboratory. No receptor has ever been identified, which is unusual after thirty years. No randomized controlled trial has been published. The 250 to 500 mcg convention appears in no study in any species, and the allometric math usually offered to justify it actually produces about 113 to 122 mcg. Those two numbers do happen to be exactly one twentieth and one tenth of a standard 5 mg vial.

There was a registry entry that looked like it was finally going to test this properly. It does not survive being looked at. The full derivation and what happened with that trial is here.

TB-500. This one has a naming problem underneath the evidence problem. What is sold as TB-500 is seven amino acids, residues 17 through 23 of a 43 amino acid peptide called thymosin beta-4. Nearly every impressive study attached to the name was run on the larger parent molecule, which the FDA has stated explicitly is not the same substance.

For the fragment actually being sold, the FDA found no published article describing it being given to a human, and no toxicology study of any kind in any species. A 2026 scoping review screened 1,772 records, included 80, and found direct evidence on TB-500 itself in exactly one of them. The full breakdown is here.

The honest read

Take those two summaries and put them next to each other.

You are looking at one compound whose effective dose has never been established and whose mechanism has no identified receptor, combined with a second compound whose research belongs to a different molecule and which has no verified human administration at all.

Then there is the part specific to the combination. I searched for any study of BPC-157 and TB-500 given together, in any species, by any route. I did not find one. I am not going to tell you none exists, because absence of a search result is not proof. What I can tell you is that if such a study is out there, nobody selling the stack is citing it.

Stacking two compounds that have not been tested individually in humans does not average out the uncertainty. It multiplies it. Whatever the odds are that either one does what is claimed, the odds that both do, together, in the way the story requires, are necessarily worse.

None of this is the same as saying they do not work. Plenty of real drugs looked exactly like this before somebody ran the trial. The problem is that in this case nobody has run the trial, and the marketing is written as though somebody did.

If you are going to do this anyway

This is the part I actually care about, because it is the part where people get hurt, and it has almost nothing to do with the molecules.

The real risk is what is in the vial. An independent analysis of TB500 products bought online found their contents were not systematically consistent with their descriptions. On the veterinary side, a racing testing laboratory analysed a batch of TB-500 labelled substances and found most contained no proteins, peptides or amino acids whatsoever. A test that finds no amino acids in a peptide product has not found a low grade peptide. It has found something that was never a peptide.

You cannot reason your way around this. If the label does not tell you what is in the bottle, nothing else on this page matters.

What you can do is demand a batch specific certificate of analysis and know how to read it. That means checking identity by mass spectrometry, purity by HPLC, and content, which is a separate number from purity and the one almost everyone skips. Here is how to read one, walked through on two real certificates.

One check specific to this stack: TB-500 has a molecular weight of about 889. Thymosin beta-4 is about 4,963. If a vendor tells you those are the same thing, their own certificate will disagree with them.

The second risk is arithmetic. Reconstitution errors are how people end up an order of magnitude off their intended dose, in either direction, using a perfectly good vial. The math is not hard, but it is unforgiving, and the syringe markings are not measuring what most people assume they are measuring. The full walkthrough is here.

The third thing is knowing what would make you stop. There is no long term safety data for either compound at any dose. For TB-500 there is no toxicology data at all, in any species, which is different from having data that came back clean. If you are competing under any anti-doping code, both are prohibited at all times, and TB-500 sits in the more serious non-Specified category carrying a four year default sanction.

My take

I have spent more time on these two compounds than on anything else I have written, and the thing that stays with me is not that the evidence is weak. Weak evidence is ordinary and honest.

It is that the confidence is manufactured. A dose that turns out to be a fraction of a vial. A research history that belongs to a different molecule. A trial registration sitting in a cluster of mock records. Every one of those reads as authoritative until you check it, and none of them is hiding, they are all just one search away.

If the stack works, it will still work after somebody tests it. If it does not, the people finding that out are the ones buying it right now.

---

If you have run this stack, the question I would actually like answered is whether you had a batch specific certificate for both vials, and what molecular weight the TB-500 one listed. Given what the testing laboratories keep finding, that answer tells us more than any story about how the shoulder felt.

---

This content is for educational and informational purposes only and is not medical advice. Peptides discussed are research compounds and may not be approved for human use. Nothing here should be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before starting any peptide, supplement, or protocol. Individual responses vary. Do not self-administer compounds without proper medical supervision.